Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Theralase Technologies Inc. V.TLT

Alternate Symbol(s):  V.TLT.WT | TLTFF

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs) and activates them with patent pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The CLT division is responsible for the Company’s medical laser business. The Cool Laser Therapy division designs, develops, manufactures and markets super-pulsed laser technology indicated for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions. The Company develops products both internally and using the assistance of specialist external resources.


TSXV:TLT - Post by User

Comment by CancerSlayeron Dec 29, 2020 10:53pm
131 Views
Post# 32194880

RE:Anti-tumour Immunity Documented in PDT of Melanoma!

RE:Anti-tumour Immunity Documented in PDT of Melanoma!Thanks Eoganacht for that find.  You are a stellar researcher of research.  This study's finding surely makes me a proud TLT shareholder.  Therapeutic cancer vaccine trials (mRNA-based & antigen/adjuvant-based) show great promise & this study further highlights our potential in this field.  Personalized cancer vaccines should also work well in those cancers where immunotherapy is effective (like melanoma, NSCLC & bladder cancer). Theralase's technology could very well add to what immunotherapeutics alone cannot accomplish, & such technology could apply to a variety of cancers imo.  It looks like Theralase is setting up for yet another promising trial(s).  Thanks again Eog...
<< Previous
Bullboard Posts
Next >>